Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet D, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18:318–27.
Nordmann P, Poirel L. Epidemiology and diagnostics of carbapenem resistance in Gram-negative bacteria. Clin Infect Dis. 2019;69:S521–8.
Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum beta-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR- P. aeruginosa). Clin Infect Dis. 2021;72:1109–16.
Madueño A, González Garcı́a J, Fernández-Romero S, Oteo J, Lecuona M. Dissemination and clinical implications of multidrug-resistant Klebsiella Pneumoniae isolates producing OXA-48 in a Spanish Hospital. J Hosp Infect. 2017;96:116–22.
Pitout JDD, Peirano G, Kock MM, Strydom KA, Matsumura Y. The Global Ascendency of OXA-48-type carbapenemases. Clin Microbiol Rev. 2019;33:e00102–19.
Carmeli Y, Armstrong J, Laud PJ, Newell P, Stone G, Wardman A, et al. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study. Lancet Infect Dis. 2016;16:661–73.
Bakthavatchalam YD, Anandan S, Veeraraghavan B. Laboratory detection and clinical implication of oxacillinase-48 like carbapenemase: the hidden threat. J Glob Infect Dis. 2016;8:41–50.
Tumbarello M, Viale P, Viscoli C, Trecarichi EM, Tumietto F, Marchese A, et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis. 2012;55:943–50.
Zarkotou O, Pournaras S, Tselioti P, Dragoumanos V, Pitiriga V, Ranellou K, et al. Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment. Clin Microbiol Infect. 2011;17:1798–803.
Hirsch EB, Tam VH. Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multi drug-resistant infection. J Antimicrob Chemother. 2010;65:1119–25.
Mataraci Kara E, Yilmaz M, İstanbullu Tosun A, Özbek Çelik B. Evaluation of the synergy of ceftazidime/avibactam in combination with colistin, doripenem, levofloxacin, tigecycline, and tobramycin against OXA-48 producing Enterobacterales. Journal Chemother. 2020;32:171–8.
Rafailidis PI, Falagas ME. Options for treating carbapenem-resistant Enterobacteriaceae. Curr Opin Infect Dis. 2014;27:479–83.
Sutcliffe JA, O’Brien W, Fyfe C, Grossman TH. Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens. Antimicrob Agents Chemother. 2013;57:5548–58.
Wu J, Zhang G, Zhao Q, Wang L, Yang J, Cui J. In vitro antimicrobial activity and dose optimization of eravacycline and other tetracycline derivatives against levofloxacin-non-susceptible and/or trimethoprim-sulfamethoxazole-resistant Stenotrophomonas maltophilia. Infect Drug Resist. 2023;16:6005–15.
Abdallah M, Olafisoye O, Cortes C, Urban C, Landman D, Quale J. Activity of eravacycline against Enterobacteriaceae and Acinetobacter baumannii, including multidrug-resistant isolates, from New York City. Antimicrob Agents Chemother. 2015;59:1802–5. 79.
Lee YR, Burton CE. Eravacycline, a newly approved fluorocycline. Eur J Clin Microbiol Infect Dis. 2019;38:1787–94.
Guan X, He L, Hu B, Hu J, Huang X, Lai G, et al. Laboratory diagnosis, clinical management and infection control of the infections caused by extensively drug-resistant Gram-negative bacilli: a Chinese consensus statement. Clin Microbiol Infect. 2016;22:S15–25.
The European Committee on Antimicrobial Susceptibility Testing Breakpoint tables for interpretation of MICs and zone diameters European Committee on Antimicrobial Susceptibility Testing. Sweden: EUCAST; 2023.
Odds FC. Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother. 2003;52:1.
Cai Y, Li R, Liang B, Bai N, Liu Y, Wang R. In vitro antimicrobial activity and mutant prevention concentration of colistin against Acinetobacter baumannii. Antimicrob Agents Chemother. 2010;54:3998–9.
Drlica K, Zhao X. Mutant selection window hypothesis updated. Clin Infect Dis. 2007;44:681–8.
Blondeau J, Zhao X, Hansen G, Drlica K. Mutant preventionconcentrations (MPC) of fluoroquinolones with clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother. 2001;45:433–8.
Blondeau JM. New concepts in antimicrobial susceptibility testing: the mutant prevention concentration and mutantselection window approach. Vet Dermatol. 2009;20:383–96.
Livermore DM, Mushtaq S, Warner M, Woodford N. In vitro activity of eravacycline against carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii. Antimicrob Agents Chemother. 2016;60:3840–4.
Zhang Y, Lin X, Bush K. In vitro susceptibility of β-lactamase-producing carbapenem-resistant Enterobacteriaceae (CRE) to eravacycline. Journal Antibiotics. 2016;69:600–4.
Zhang Y, Liu D, Liu Y, Li Q, Liu H, Zhou P, et al. Detection and characterization of eravacycline heteroresistance in clinical bacterial isolates. Front Microbiol. 2024;15:1332458.
Diaz-Diaz S, Yerbes P, Recacha E, De Gregorio-Iaria B, Pulido MR, Romero-Muñoz M, et al. RecA inactivation as a strategy to reverse the heteroresistance phenomenon in clinical isolates of Escherichia coli. Int J Antimicrob Agents. 2023;61:106721.
Sánchez-León I, García-Martínez T, Diene SM, Pérez-Nadales E, Martínez-Martínez L, Rolain JM. Heteroresistance to Colistin in clinical isolates of Klebsiella pneumoniae producing OXA-48. Antibiotics. 2023;12:1111.
Klein EY, Van Boeckel TP, Martinez EM, Pant S, Gandra S, Levin AS, et al. Global increase and geographic convergence in antibiotic consumption between 2000 and 2015. Proc Natl Acad Sci. 2018;115:E3463–70.
Liu YY, Wang Y, Walsh TR, Yi LX, Zhang R, Spencer J, et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis. 2016b;16:161–8.
Falagas ME, Kastoris AC, Kapaskelis AM. Karagoergopoulos DE. Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infect Dis. 2010;10:43–50.
Grabein B, Graninger W, Rodríguez Baño J, Dinh A, Liesenfeld DB. Intravenous fosfomycin—back to the future. Systematic review and meta-analysis of the clinical literature. Clin Microbiol Infect. 2017;23:363–72.
Petrosillo N, Giannella M, Lewis R, Viale P. Treatment of carbapenem resistant Klebsiella pneumoniae: the state of the art. Expert Rev Anti Infect Ther. 2013;11:159–77.
Firsov AA, Strukova EN, Shlykova DS, Portnoy YA, Kozyreva VK, Edelstein MV, et al. Bacterial Resistance Studies Using In Vitro Dynamic Models: the Predictive Power of the Mutant Prevention and Minimum Inhibitory Antibiotic Concentrations. Antimicrob Agents Chemother. 2013;57:4956–62.
Strukova EN, Portnoy YA, Romanov AV, Edelstein MV, Zinner SH, Firsov AA. Searching for the Optimal Predictor of Ciprofloxacin Resistance in Klebsiella pneumoniae by Using In Vitro Dynamic Models. Antimicrob Agents Chemother. 2015;60:1208–15.
Allen GP, Kaatz GW, Rybak MJ. In vitro activities of mutant prevention concentration-targeted concentrations of fluoroquinolones against Staphylococcus aureus in a pharmacodynamic model. Int J Antimicrob Agents. 2004;24:150–60.
Krogstad DJ, Moellering RC Antimicrobial combinations. In: Lorian V, editor. Antibiotics in Laboratory Medicine 2. Baltimore: William & Wilkins, 1986
Rodríguez-Baño J, Gutiérrez-Gutiérrez B, Machuca I, Pascual A. Treatment of infections caused by extended-spectrum-beta lactamase-,AmpC- and carbapenemase producing Enterobacteriaceae. Clin Microbio Rev. 2018;31:e00079-17.
Li Y, Cui L, Xue F, Wang Q, Zheng B. Synergism of eravacycline combined with other antimicrobial agents against carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii. Journal Glob Antimicrobial Resistance. 2022;30:56–9.
Rahul R, Maheswary D, Damodaran N, Leela KV. Eravacycline-Synergistic activity with other antimicrobials in carbapenem resistant isolates of Escherichia coli and Acinetobacter baumannii. Diag Micro Infect Dis. 2023;107:116006.
Camargo JF, Simkins J, Beduschi T, Tekin A, Aragon L, Pérez-Cardona A, et al. Successful treatment of carbapenemase-producing pandrug-resistant Klebsiella pneumoniae bacteremia. Antimicrob Agents Chemother. 2015;59:5903–8.
Brennan-Krohn T, Kirby JE. Synergistic combinations and repurposed antibiotics active against the pan drug-resistant Klebsiella pneumoniae Nevada strain. Antimicrob Agents Chemother. 2019;63:e01374–19.
Ramirez MS, Tolmasky ME. Aminoglycoside-modifying enzymes. Drug Resist Updat. 2010;13:151–71.
Endimiani A, Hujer AM, Perez F, Bethel CR, Hujer KM, Kroeger J, et al. Characterization of blaKPC-containing Klebsiella pneumoniae isolates detected in different institutions in the Eastern USA. J Antimicrob Chemother. 2009;63:427–37.
Paterson DL, Bonomo R. Extended-spectrum beta-lactamase: a clinicalupdate. Clin Microbiol Rev. 2005;18:657–86.
Pitout JD, Laupland KB. Extended-spectrum beta-lactamase producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis. 2008;8:159–66.
Rodríguez-Martínez JM, Machuca J, Cano ME, Calvo J, Martínez-Martínez L, Pascual A. Plasmid-mediated quinolone resistance: two decades on. Drug Resist Updat. 2016;29:13–29.
